Clinical Trial Update: Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial investigating oral tolerance to reduce peanut reactivity in individuals with peanut allergy as part of an anti-IgE approach; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Food Allergy
• Peanut Allergy

Drugs mentioned

• Anti-IgE therapy (unspecified in provided data)

Snippet

Sponsor: Boston Children's Hospital | Conditions: Peanut Allergy, Food Allergy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-03